AstraZeneca has launched a lawsuit against the Mississippi Attorney General, marking a significant moment in the escalating confrontations between large pharmaceutical companies and state governments. The lawsuit delves into the utilization of the federal 340B drug pricing program, which is designed to help low-income patients by mandating that drug manufacturers provide outpatient drugs to eligible health care organizations at significantly reduced prices. However, the pharmaceutical companies argue that this program has been exploited, leading to disputes with local medical providers and pharmacies. AstraZeneca’s recent legal actions underscore the tension in the ongoing battle over drug pricing and regulation.
For in-depth details about this case and the broader implications for the pharmaceutical industry, refer to the original article on Law.com.